Pharvaris (NASDAQ:PHVS) Trading 4.3% Higher – Still a Buy?

Pharvaris (NASDAQ:PHVS) shot up 4.3% during trading on Thursday . The stock traded as high as $16.65 and last traded at $16.70. 13,304 shares traded hands during mid-day trading, a decline of 81% from the average session volume of 71,180 shares. The stock had previously closed at $16.01.

Analyst Upgrades and Downgrades

Separately, JMP Securities increased their price target on shares of Pharvaris from $46.00 to $55.00 and gave the stock a “market outperform” rating in a research note on Friday, January 31st.

Pharvaris Trading Up 5.6 %

The company’s 50 day moving average is $17.20 and its 200-day moving average is $19.15. The company has a market capitalization of $883.70 million, a P/E ratio of -6.10 and a beta of -3.02.

Institutional Trading of Pharvaris

Several institutional investors have recently bought and sold shares of PHVS. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in Pharvaris during the 3rd quarter valued at about $906,000. HighVista Strategies LLC grew its position in Pharvaris by 35.9% during the 3rd quarter. HighVista Strategies LLC now owns 22,768 shares of the company’s stock valued at $422,000 after purchasing an additional 6,018 shares during the last quarter. Patient Square Capital LP purchased a new stake in Pharvaris during the 3rd quarter valued at about $4,488,000. State Street Corp purchased a new stake in Pharvaris during the 3rd quarter valued at about $1,000,000. Finally, Sphera Funds Management LTD. grew its position in Pharvaris by 8.9% during the 3rd quarter. Sphera Funds Management LTD. now owns 439,292 shares of the company’s stock valued at $8,136,000 after purchasing an additional 36,027 shares during the last quarter.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.